Imat Tablet (Imatinib)

Medicine OverView

Product Code:
1086
Manufacturer :
Zydus Cadila Pharma
Country of Origin :
India
Dosage Form :
Tablets
Indication :
Blood cancer (Chronic myeloid leukaemia), Gastrointestinal stromal tumour
Packaging :
10 Tablets in strip
Active Ingredient :
Imatinib

A Product From:

Imat 100 Tablet (Imatinib 100mg)
100mg Price: Price/unit Quantity
30 Tablet/s
$20.00
$0.67 /Piece
60 Tablet/s
$39.00
$0.65 /Piece
90 Tablet/s
$57.00
$0.63 /Piece
Imat 400 Tablet (Imatinib 400mg)
400mg Price: Price/unit Quantity
30 Tablet/s
$30.00
$1.00 /Piece
60 Tablet/s
$58.00
$0.97 /Piece
90 Tablet/s
$86.00
$0.96 /Piece

Description

Buy Imat tablet 100mg, and 400mg tablet Generic drug of Imatinib online at a cheapest price from most trusted pharmacy to cure Blood cancer (Chronic myeloid leukemia), Gastrointestinal stromal tumor. Get all detail regarding this medicine like the review, use, side effect (major/minor), dosage (Missed/Over), Composition, Substitutes, Precautions, manufactured by Zydus Cadila Pharma, how it works, how long does last and many more. You can also get fast delivery in Australia, UK, USA, France, China.

This medicine is composition of Imatinib mesylate I.P. equivalent to 100 mg / 400 mg of Imatinib freebase.generic Imatinib is designated chemically, as 4-[(4-Methyl-1-piperazinyl) methyl]-N-4{4 methyl-3- [(4- (3 - pyridinyl) -2 - pyrimidinyl) amino ]-phenyl} benzamide methanesulphonate.

This medicine is a protein-tyrosine kinase inhibitor that inhibits that Bcr-Ab tyrosine kinase. The constitutive abnormal tyrosine kinase generated by the Philadelphia chromosome abnormality in chronic myeloid leukemia.

This medicine is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (SCF), c-kit, and inhibit PDGF -and SCF mediated cellular events. In vitro, Imatinib medicine inhibits proliferation and induces apoptosis in gastrointestinal stromal tumor (GIST) cell which expresses an activating c-kit mutation.

The IMAT 100mg tablet is indicated for the treatment of patients with -Philadelphia chromosome-positive chronic myeloid leukemia (CML) in blast crisis. Accelerated phase or in chronic phase after failure of interferon-alpha therapy.

This pill is also indicated for the treatment of patients with the kit (CD117) positive unresectable and/or metastatic malignant GIST.

Imat 400 mg Tablet is an anti-cancer medication. It works by obstructing the activity of the abnormal protein that signs disease cells to duplicate. This stops or moderates the spread of growth cells.

Take this drug in the dose and duration as suggested by your family doctor. Swallow it as a whole. Do not chew, crush or break it. This Tablet is to be taken with food.

The proper information about how long does it last is printed on the tablet box or the tablet strip. It is available 10 Tablets in a strip. The imat 100mg/400mg pill is available Iron oxide Yellow and Titanium Dioxide IP. 400mg tablet is Iron oxide Red and Titanium Dioxide IP.

Store below 30 C. protects from light & moisture.

Treatment ought to be started by a doctor experienced in the treatment of patients with perpetual myeloid leukemia or gastrointestinal stromal tumors.

The prescribed dose should be administered orally. With a meal(food) and a large glass of water. Doses of 400 mg should be administered once daily.

Treatment might have proceeded insofar as there is no proof of dynamic ailment or unsuitable foxicity.

Unresectable and/or metastatic. Maligsnant GIST -400 mg/day.

Loss of a previously achieved hematologic response.

Dose adjustment for hepatotoxicity and other Non-Hematologic major Reactions.

On the off chance that a severe non-hematologic antagonistic response grows, (for example, extreme hepatotoxicity or severe liquid maintenance), Imatinib mesylate ought to be withheld until the point that the occasion has settled.

After that, treatment can be resumed as appropriate depending on the initial severity of the event.

Missed Dose

Take the missed dose as soon as you memorize. If it is almost time for the next scheduled dose, then the missed dose can be skipped. Contact your family doctor for further instructions if you miss more than one scheduled dose of this medicine.

OverDose

Experience with dosage greater then 400 mg is limited. In the event of overdosage, the patients should be observed and appropriate supportive treatment given.

Chronic Myeloid Leukemia

Majority of generic Imatinib mesylate-treated patients experience adverse events at some time. Most events are mild to moderate grade. The most frequently reported drug-related side effects are nausea, vomiting, diarrhea, edema, and muscle cramps. Edema is most frequently periorbital or in lower limbs and is managed with diuretics. Other supportive measures, or by reducing the dosage of this medication(see Dosage and Administration).

A variety of adverse events represent local/ general fluid retention including pleural effusion, pulmonary edema, ascites, and rapid weight gain or without superficial edema. These events appear to be dose-related, are more common in the blast crisis and accelerated phase studies (where the dose is 600 mg/day) and are common in the elderly. These events are usually managed by interrupting Imatinib mesylate treatment and with diuretics or other appropriate supportive care measures.

Hematologic Toxicity

Elevation of transaminases or bilirubin may occur. It is usually managed with dose reduction or interruption.

Gastrointestinal Stromal Tumors

Majority of Imatinib mesylate patient’s experience adverse event at some time. The most frequently reported adverse effect are edema, diarrhea, abdominal pain muscle cramps fatigue, nausea, and rash. Most events are of mild-moderate severity.

As per the expert’s review, there are some side effects of imat tablets. They are as follows:

Minor side effect

  • Diarrhea
  • Nausea and Vomiting
  • Mouth sores
  • Loss of appetite
  • Altered sense of taste
  • Heartburn and indigestion
  • Joint pain, stiffness, and swelling
  • Burning or tingling sensation of skin
  • Difficulty in falling or staying asleep
  • Skin rash, hives, or itching
  • Hair loss or thinning of the hair

Major side effect

  • Swelling around the eyes
  • Swelling or the hands, feet, ankle, and lower legs
  • Severe breathing difficulty
  • Fast/irregular heartbeat
  • Presence of blood in a cough
  • Yellowing of skin and eyes
  • Unusual bleeding or bruising
  • Abdominal pain or bloating
  • Bloody stool

General Instructions

Edema and Fluid retention

Imatinib mesylate is often associated with edema and occasionally severe fluid retention.patients should be weighed and monitored regularly. For symptoms of fluid retention. An unexpected rapid weight gain should be correctly investigated and appropriate treatment provided.

Gliritation Imatinib mesylate is sometimes associated with Gliritation.imat should be taken with food and a large glass of water to minimize this issue.

Hemorrhage

In patients with GIST, gastrointestinal bleeds or intra-tumoral bleeds or both may occur from gastrointestinal tumor sites.

Hematologic danger

Treatment with Imatinib mesylate is related with neutropenia or thrombocytopenia. Finish blood check ought to be performed week after week for the main month. Every more(other) week for the second month, and occasionally from that point as clinically showed. In CML, the event of these cytopenias is reliant on the phase of malady and is more successive in patients with unending stage CML (see Dosage and Administration).

Hepatoxicity

Hepatotoxicity, occasionally severe. May occur with Imatinib Mesylate. Liver function should be monitored before of treatment and monthly/ as clinically indicated. Laboratory abnormalities should be managed with.

Interruption or Dose reduction of the treatment with Imatinib Mesylate. (see Dosage). Sufferer with hepatic impairment should be closely monitored because exposure to Imatinib mesylate may be increased. As there are no clinical studies of this medicine mesylate in suffere with impaired liver problem, no specific suggestion concerning initial dosing adjustment can be given.

Toxicities from long term use

Because follow-up of most patients treated with Imatinib is relatively short, there are no long term safety data.

General Warning

Pediatric

The safety and efficacy of Imatinib mesylate inpatient under the age of 18 years have not been using.

Pregnancy

lady of childbearing potential should be advised to avoid becoming pregnant. If Imatinib mesylate is used during pregnancy or if the patient becomes pregnant while taking Imatinib mesylate the patient should be apprised of the potential hazzard the fetus.

When not to use?

Nursing Mothers

It is not known whether this medication mesylate or its metabolites are excreted in woman milk.

Pediatric Use

The effectiveness and safety of Imatinib mesylate in pediatric patients have not been established.

Geriatric Use

The efficacy of this drug was similar in older and younger patients.

Warnings for special population

Imat pill should not be prescribed to women who are pregnant or are breastfeeding a child.

Drugs that may increase Imatinib plasma concentrations

Caution is recommended when administering this medication with an inhibitor of the CYP3A4 family (e.g., ketoconazole, itraconazole; erythromycin, clarithromycin).

A substance that inhibitor the cytochrome P450 isoenzyme (CYP3A4) activity may decrease metabolism and increase Imatinib concentration. There is a major increase in exposure to Imatinib when Imatinib mesylate is co-administered with ketoconazole (CYP3A4 inhibitor).

Drugs that may decrease Imatinib plasma concentrations

A substance that is an inducer of CYP3A4 activity may increase metabolism and decrease Imatinib plasma concentration Co-medication that induce CYP3A4 (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, phenobarbital or St.john’s Wort) may reduce exposure to Imatinib mesylate.

medicine that may have their plasma concentration altered by generic Imatinib

Imatinib increases the mean C and AUC of simvastatin (CYP3A4 substrate) 2 and 3-5- fold, respectively. Recommending a hindrance of the CYP3A4 by Imatinib. The specific alert is prescribed while directing Imat medication with CYP3A4 substrates that have a thin helpful window (e.g., triazole-benzodiazepines, dihydropyridine calcium channel blockers, particular HMG-CoA reductase inhibitors).

Since CYP2C9 and CYP3A4 utilize warfarin.

Patients who require anticoagulation ought to get low atomic weight standard heparin.

In vitro, Imatinib mesylate inhibits the cytochrome P450 isoenzymes CYP2D6 activity at a similar concentration that affects CYP3A4 activity. Fundamental introduction to substrates of CYP2D6 is required to be expanded when co-managed with Imatinib Mesylate. No particular investigations have been performed, and alert is prescribed.

Cancer-causing nature thinks about have not been performed with Imatinib Mesylate. Imatinib was not genotoxic when tried in an in vitro bacterial cell measure (Ames rest). An in vitro mammalian cell test (mouse lymphoma) and an in vitro rodent micronucleus test. In male rats, the maximum Clinical dose caused decreased in testicular and epididymal weights and percent motile sperms. At maximum clinical dose. Female rats had a significant post-implantation fetal loss and a reduced number of live fetuses. These effects on fertility were not seen with the use of lower doses.

Hematologic Adverse Reaction

Dose reduction/ treatment interruptions for severe neutropenia and thrombocytopenia are recommended.

utilized of Imatinib mesylate is contraindicated in patients with hypersensitivity to IMatinib mesylate or any other component of Imatinib mesylate.

Products Reviews

Average Rating
0

5 star
4 star
3 star
2 star
1 star

(Based On 0 reviews Rating)

Write Review

What do you think about this product?

    Bad           Good

Safety & Securities